Aevi Genomic Medicine Inc (NASDAQ:GNMX) saw unusually-strong trading volume on Thursday . Approximately 6,247,662 shares were traded during trading, an increase of 74% from the previous session’s volume of 3,597,828 shares.The stock last traded at $0.25 and had previously closed at $0.21.

Several equities research analysts have recently commented on GNMX shares. JMP Securities lowered shares of Aevi Genomic Medicine from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 3rd. ValuEngine lowered shares of Aevi Genomic Medicine from a “hold” rating to a “sell” rating in a research report on Thursday, December 20th.

The firm has a market capitalization of $13.86 million, a PE ratio of -0.29 and a beta of 0.41.

A hedge fund recently bought a new stake in Aevi Genomic Medicine stock. Bridgeway Capital Management Inc. acquired a new stake in Aevi Genomic Medicine Inc (NASDAQ:GNMX) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 223,500 shares of the biotechnology company’s stock, valued at approximately $275,000. Bridgeway Capital Management Inc. owned approximately 0.35% of Aevi Genomic Medicine at the end of the most recent reporting period. 19.61% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Aevi Genomic Medicine (GNMX) Sees Strong Trading Volume” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at

About Aevi Genomic Medicine (NASDAQ:GNMX)

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.

Featured Article: Roth IRA

Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with's FREE daily email newsletter.